Market Movers compiles the best reactions from investors and analysts on Biogen. Experts discussed the biotech company after the Food and Drug Administration approved Leqembi for Alzheimer’s disease, paving the way for broader Medicare coverage. The drug slowed cognitive decline in trials, but carries a risk of brain swelling and bleeding and comes with a price tag of $26,500 per year. Biogen has partnered with Japanese pharmaceutical company Eisai to produce Leqembi. Despite the approval, Biogen stock was down more than 3% at market close on Friday and is down nearly 10% over the past month.